LPL Financial
CADL icon

LPL Financial’s Candel Therapeutics CADL Stock Holding History

LPL Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Sell
24,702
-3,951
-14% -$21.5K ﹤0.01% 5635
2025
Q4 		$162K Buy
28,653
+7,250
+34% +$39K ﹤0.01% 5508
2025
Q3 		$109K Sell
21,403
-46,490
-68% -$269K ﹤0.01% 5496
2025
Q2 		$344K Buy
+67,893
New +$349K ﹤0.01% 4681
2025
Q1 		– Sell
-10,703
Closed -$92.9K – 5373
2024
Q4 		$92.9K Buy
+10,703
New +$63.2K ﹤0.01% 5006

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LPL Financial's CADL Position: Q1 2026 in Review

LPL Financial reduced its Candel Therapeutics (CADL) stake by 14% in Q1 2026, selling an estimated $21.5K and leaving 24,702 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #5635.

LPL Financial first reported a position in CADL in Q4 2024 and has held it in 5 quarters since. The position peaked at $344K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • LPL Financial held 24,702 shares of Candel Therapeutics worth $121K as of Q1 2026.
  • LPL Financial sold 3,951 Candel Therapeutics shares in Q1 2026, an estimated $21.5K.
  • Candel Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5635 holding.
  • LPL Financial first reported a position in Candel Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • LPL Financial's Candel Therapeutics position peaked at $344K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.